Short answer: CJC-1295 is a GHRH analog (pituitary GHRH receptor); ipamorelin is a GHRP (ghrelin/GHSR receptor). They target different pathways and are frequently studied in combination because their mechanisms are synergistic — not redundant.
Disclosure: This page contains affiliate links. We may earn from qualifying purchases. See our full disclosure.
| Criteria | CJC-1295 | Ipamorelin |
|---|---|---|
| Receptor target | GHRH receptor | Ghrelin/GHSR receptor |
| GH effect | Sustained elevation | Precise, controlled pulses |
| Cortisol/prolactin effect | Minimal | Minimal (most selective GHRP) |
| Research use case | GHRH axis studies | Ghrelin pathway + selective GH |
Current research deal — use code SOL
10% off CJC-1295 and ipamorelin research compounds at Live Alpha Labs. Credit cards accepted. For research use only. We may earn from qualifying purchases.
Brand comparison
Related compound
Category hub
All current offers
CJC-1295 is a GHRH (growth hormone releasing hormone) analog that stimulates the pituitary to release GH via GHRH receptors. Ipamorelin is a GHRP (growth hormone releasing peptide) that acts via the ghrelin receptor (GHSR). They target different upstream pathways that converge on GH release — which is why research frequently studies them together.